GL1X · GenesisL1 explorer

MolNFT v1 · #120808 · protein

Structure of esterase EST22 mutant-S188A with P-nitrophenol

5HC2 · Lipolytic enzyme: “Structure of esterase EST22 mutant-S188A with P-nitrophenol”. X-ray diffraction, 1 ligand (NPO), 12 pockets (best druggability 0.83). MolNFT v1 #120808 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
5HC2
Type
protein
Length
1,371 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Lipolytic enzyme
EC
3.1.1.-
UniProt
H6BDX1
Ligands
NPO
Pockets
12 · best druggability 0.83

Structure

x-ray diffraction · 2 distinct chains · 40% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, C, DLipolytic enzyme (EC 3.1.1.-)protein34339% helix, 18% strandH6BDX1
BLipolytic enzyme (EC 3.1.1.-)protein34240% helix, 18% strandH6BDX1

Ligands and binding sites

  • NPO · P-nitrophenol · ligand · 4 copies · chains A, B, C, D
  • IMD · Imidazole · additive · 5 copies · chains A, B, C, D

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

12 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111850.830.84120NPO, IMD
25440.790.8548NPO, IMD
35550.780.8447NPO, IMD
410590.750.78131empty
51010.460.8018empty

Interfaces

5 interfaces between chains.

  • C–D · 1151 Ų buried · 17 hydrogen bonds · protein-protein
  • A–B · 1142 Ų buried · 15 hydrogen bonds · protein-protein
  • B–C · 538 Ų buried · 0 hydrogen bonds · protein-protein
  • B–D · 147 Ų buried · 1 hydrogen bond · protein-protein
  • A–C · 143 Ų buried · 1 hydrogen bond · protein-protein

Compared structures

  • 5HC2 · Structure of esterase Est22 mutant-S188A with p-nitrophenol · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.